We are happy to announce the development of two new important strategic partnerships moving into 2017. One will be to support Grunenthal, a German based pharmaceutical manufacturer launch APO-go® in the Nordic region and the other to support PaxVax, a US based vaccine manufacturer to develop the Vivotif® brand book. APO-go® is a treatment for Parkinson’s Disease (PD), and Vivotif® is an oral vaccine against typhoid fever. These partnerships further broaden W’s Life Science Business Unit, which now includes medtech, pharmaceutical and vaccine manufacturers.
Read all about our Life Science client here